Business Wire·Oct 13, 2026, 7:00 AM ET

United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting

Ralinepag reduced clinical worsening risk in pulmonary arterial hypertension patients across all noninvasive low-risk baseline profiles per ADVANCE OUTCOMES subgroup analysis.
Nebulized treprostinil significantly reduced multiple disease progression event risks compared to placebo in idiopathic pulmonary fibrosis patients per TETON-2 post-hoc analysis.
Interim PHINDER study data showed interstitial lung disease patients, particularly those with idiopathic pulmonary fibrosis, have numerically higher mortality risk scores.
DeciPHer-ILD registry interim analysis found pulmonary hypertension-interstitial lung disease patients exhibit poor hemodynamics, impaired functional class, & reduced exercise capacity.
United Therapeutics announced two oral presentations & five poster presentations for the CHEST 2026 Annual Meeting in Phoenix, Arizona.
The company will host the "Time to Look Closer" symposium featuring preliminary PHINDER data on pulmonary hypertension-interstitial lung disease screening.
FDA accepted the New Drug Application for ralinepag to treat pulmonary arterial hypertension & the supplemental New Drug Application for nebulized treprostinil to treat idiopathic pulmonary fibrosis.
Both ralinepag for pulmonary arterial hypertension & nebulized treprostinil for idiopathic pulmonary fibrosis remain investigational & unapproved by the FDA.